biostudies-literatureBlair YANational Heart, Lung, and Blood InstituteNational Institutes of HealthIndian Health ServiceNational Institute on Minority Health and Health DisparitiesNational Institute on AgingNational Eye InstituteCenters for Disease Control and PreventionNIDDK NIH HHSOffice of Research on Women&apos;s HealthNational Cancer InstituteAmerican Diabetes AssociationNIDDKNational Institute of Child Health and Human Development108669https://www.ebi.ac.uk/biostudies/studies/S-EPMC10922921biostudies-literatureUnknown38(2)<h4>Objective</h4>To determine burden and identify correlates of erectile dysfunction (ED) among men with prediabetes (PreD) and type 2 diabetes (T2D) enrolled in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS).<h4>Research design and methods</h4>The 2017 DPPOS visit included administration of the International Index of Erectile Function. Of 648 male participants, 88 % (n = 568) completed the survey. Associations between sociodemographic, behavioral, clinical, and glycemic measures at time of ED assessment, and ED were examined using multivariable logistic regression models in men with PreD and T2D separately.<h4>Results</h4>Overall, 218 (38 %) men met ED criteria. Prevalence was similar in men with PreD (41 %) and T2D (37 %) (p = 0.4). In all men, age (p < 0.001) increased odds of ED. Among men with PreD, those assigned to intensive lifestyle intervention (ILS), but not metformin, had decreased odds of ED compared with the placebo group (OR = 0.35, 95 % CI = 0.13, 0.94). Non-Hispanic White race was associated with increased odds of ED compared with other races (OR = 4.3; 95 % CI = 1.92, 9.65). Among men with T2D, ED risk did not differ by DPP treatment assignment; however, individuals with metabolic syndrome defined by National Cholesterol Education Program criteria, had increased odds of ED (OR = 1.85, 95 % CI = 1.14, 3.01), as did individuals with depression (OR = 2.05; 95 % CI = 1.10, 3.79).<h4>Conclusions</h4>ED is prevalent in men with PreD and T2D. Our finding of reduced odds of ED in men randomized to ILS and with PreD suggests a potential opportunity for risk mitigation in the prediabetes interval. In men who have progressed to T2D, metabolic factors appear to be associated with ED.Journal of diabetes and its complicationsPrevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcomes study.PMC10922921U01 DK048407U24 DK115255U01 DK115255U01 DK048349U01 DK048404SCR_001415U01 DK048406U01 DK048443U01 DK048400U01 DK048489U01 DK048468U01 DK076169U01 DK048485U01 DK048387U01 DK048380U01 DK048381U24 DK076169U01 DK048437U01 DK048514U01 DK048339U01 DK048377U01 DK048411U01 DK048434U01 DK048412U01 DK048413U01 DK048397U01 DK048375Temprosa MGadde KMWessells HDoherty LBlair YAPop-Busui RSingh PDiabetes Prevention Program Research GroupOwora AHSarma AVfalsePrevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcomes study.<h4>Objective</h4>To determine burden and identify correlates of erectile dysfunction (ED) among men with prediabetes (PreD) and type 2 diabetes (T2D) enrolled in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS).<h4>Research design and methods</h4>The 2017 DPPOS visit included administration of the International Index of Erectile Function. Of 648 male participants, 88 % (n = 568) completed the survey. Associations between sociodemographic, behavioral, clinical, and glycemic measures at time of ED assessment, and ED were examined using multivariable logistic regression models in men with PreD and T2D separately.<h4>Results</h4>Overall, 218 (38 %) men met ED criteria. Prevalence was similar in men with PreD (41 %) and T2D (37 %) (p = 0.4). In all men, age (p < 0.001) increased odds of ED. Among men with PreD, those assigned to intensive lifestyle intervention (ILS), but not metformin, had decreased odds of ED compared with the placebo group (OR = 0.35, 95 % CI = 0.13, 0.94). Non-Hispanic White race was associated with increased odds of ED compared with other races (OR = 4.3; 95 % CI = 1.92, 9.65). Among men with T2D, ED risk did not differ by DPP treatment assignment; however, individuals with metabolic syndrome defined by National Cholesterol Education Program criteria, had increased odds of ED (OR = 1.85, 95 % CI = 1.14, 3.01), as did individuals with depression (OR = 2.05; 95 % CI = 1.10, 3.79).<h4>Conclusions</h4>ED is prevalent in men with PreD and T2D. Our finding of reduced odds of ED in men randomized to ILS and with PreD suggests a potential opportunity for risk mitigation in the prediabetes interval. In men who have progressed to T2D, metabolic factors appear to be associated with ED.2024-01-01T00:00:00Z2024 Feb2026-06-01T05:07:24.863Z2025-04-05T10:19:13.387ZS-EPMC109229213821933410.1016/j.jdiacomp.2023.108669